Linked Life Data

10352648

Source:http://linkedlifedata.com/resource/pubmed/id/10352648

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-6-17
pubmed:abstractText
In the present study we assessed the frequency and characteristics of the main causes of morbidity and mortality in SLE during a 5-year period and analyzed the prognostic significance for morbidity and mortality of the main immunologic parameters used in clinical practice. We started in 1990 a multicenter study of 1,000 patients from 7 European countries. All had medical histories documented and underwent medical interview and routine general physical examination when entered in the study, and all were followed prospectively by the same physicians during the ensuing 5 years (1990-1995). Four hundred thirteen patients (41.3%) presented 1 or more episodes of arthritis, 264 (26.4%) had malar rash, 222 (22.2%) active nephropathy, 139 (13.9%) fever, 136 (13.6%) neurologic involvement, 132 (13.2%) Raynaud phenomenon, 129 (12.9%) serositis (pleuritis and/or pericarditis), 95 (9.5%) thrombocytopenia, and 72 (7.2%) thrombosis. Two hundred seventy patients (27%) presented infections, 113 (11.3%) hypertension, 75 (7.5%) osteoporosis, and 59 (5.9%) cytopenia due to immunosuppressive agents. Sixteen patients (1.6%) developed malignancies, with the most frequent primary localizations the uterus and the breast. Several immunologic parameters (anti-dsDNA or antiphospholipid antibodies) were found to have a predictive value for the development of SLE manifestations during the period of the study. Forty-five patients (4.5%) died; the most frequent causes of death were divided similarly among active SLE (28.9%), infections (28.9%), and thromboses (26.7%). A survival probability of 95% at 5 years was found. A lower survival probability (92%) was detected in those patients who presented at the beginning of the study with nephropathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0025-7974
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
167-75
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10352648-Adolescent, pubmed-meshheading:10352648-Adult, pubmed-meshheading:10352648-Aged, pubmed-meshheading:10352648-Aged, 80 and over, pubmed-meshheading:10352648-Cause of Death, pubmed-meshheading:10352648-Chi-Square Distribution, pubmed-meshheading:10352648-Child, pubmed-meshheading:10352648-Child, Preschool, pubmed-meshheading:10352648-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:10352648-Europe, pubmed-meshheading:10352648-Female, pubmed-meshheading:10352648-Fluorescent Antibody Technique, Direct, pubmed-meshheading:10352648-Humans, pubmed-meshheading:10352648-Logistic Models, pubmed-meshheading:10352648-Lupus Erythematosus, Systemic, pubmed-meshheading:10352648-Male, pubmed-meshheading:10352648-Middle Aged, pubmed-meshheading:10352648-Predictive Value of Tests, pubmed-meshheading:10352648-Prospective Studies, pubmed-meshheading:10352648-Survival Analysis
pubmed:year
1999
pubmed:articleTitle
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus.
pubmed:affiliation
Department of Medicine, Hospital Clínic, School of Medicine, University of Barcelona, Catalonia, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study